Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Scientists found a smarter way to sneak drugs past the brain's tough security system. Researchers at the University of Eastern Finland discovered that a protein called SMVT — which normally ferries vitamins into the body — can also transport creatine derivatives into the brain. The finding could be a game-changer for treating Creatine Transporter Deficiency Syndrome and potentially other neurological disorders.
Getting drugs into the brain is notoriously hard — the blood-brain barrier acts like a strict gatekeeper, blocking most compounds from entering. But researchers at the University of Eastern Finland may have found a clever workaround: using the brain's own nutrient delivery system as a vehicle for therapeutic compounds.
The team discovered that the sodium-dependent multivitamin transporter (SMVT) — a protein that naturally shuttles vitamins and essential nutrients — can also carry creatine derivatives across the blood-brain barrier. This is particularly significant for patients with Creatine Transporter Deficiency Syndrome (CTDS), a rare but serious neurological condition where creatine can't reach the brain, leading to developmental disabilities. Beyond CTDS, the researchers believe SMVT could serve as a broader delivery vehicle for other therapeutic compounds targeting the brain, potentially enabling more precise treatments for a range of neurological disorders.
Key Takeaways:
Why it matters: The blood-brain barrier has long been one of the biggest obstacles in pharmaceutical research. Harnessing a naturally occurring transporter protein could open a more efficient and targeted pathway for treating neurological conditions that have historically been difficult to address.
